Development in efficacy assessment in relevant oncology models for breast cancer nanomedicine

Abstract Breast cancer still remains a challenge worldwide, as many breast cancer patients are developing resistance to conventional therapies. Nanomedicine is among one of the important approaches, which increases the therapeutic potential of the existing drugs by delivering anticancer drugs at their target sites. These nanomedicines of anticancer drugs need to be evaluated in a relevant preclinical animal model before being tested in human being for assessing their pharmacokinetic and pharmacodynamic (PK-PD) behaviors. However, developing a suitable animal model that mimics the tumor condition in human beings is challenging, as the PK-PD of drugs and its formulations differ in human and animals. In this regard, this chapter provides a variety of preclinical animal models, their selection criteria, and characteristics of each model, which could help in selecting a relevant model for evaluating breast cancer nanomedicine that will provide greater success in preclinical and clinical trials.